Holen Sie sich die Stockscreener-App
2.37
0.42%
0.01
Schlusskurs vom Vortag:
$2.36
Offen:
$2.37
24-Stunden-Volumen:
65,738
Relative Volume:
0.46
Marktkapitalisierung:
$23.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.64M
KGV:
-0.5424
EPS:
-4.3698
Netto-Cashflow:
$-33.40M
1W Leistung:
+11.79%
1M Leistung:
-46.14%
6M Leistung:
-75.51%
1J Leistung:
-82.21%
1-Tages-Spanne:
$2.22
$2.39
1-Wochen-Bereich:
$2.14
$2.60
52-Wochen-Spanne:
$1.70
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.37 | 23.64M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics sends Sandra S Hammer to AACR rare cancer event in Vancouver - Traders Union
Price to cash flow ratio of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
ATOS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Investor ReactionQuarterly Profit Report - dars.gov.et
ATOSSA THERAPEUTICS, INC. explores lessons from COVID-19 for future biosecurity strategies - Traders Union
Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - AOL.com
ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com South Africa
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Rodman & Renshaw initiates Atossa Genetics stock with buy rating - Investing.com
ATOSAtossa Therapeutics Inc Short Interest - Finviz
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Nigeria
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Index - marketscreener.com
Price to book forward of Atossa Therapeutics, Inc. – NASDAQ:ATOS - TradingView
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Value Benchmark - marketscreener.com
Atossa Therapeutics, Inc. adopts integrated biologic signals to advance breast cancer research - Traders Union
Price to sales forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Price to book forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Price to earnings forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic? - simplywall.st
Atossa Therapeutics Inc (ATOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atossa Therapeutics Inc (ATOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atossa Therapeutics Inc (ATOS) Institutional Confidence - TradingKey
Atossa Therapeutics Inc (ATOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa Therapeutics closes $4.5M registered direct offering - Investing.com
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PR Newswire
Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0
Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union
Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan
Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Top Midday Decliners - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com
Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):